IFNG and cancer: This would make IFNγ a promising strategy in the case of relatively ‘’immune cold’’ cancers, such as metastatic castration-resistant prostate cancer (mCRPC), which is characterized by a low tumor mutational burden and few tumor infiltrating T cells, and are relatively resistant to ICBs13.